Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.70 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.64 |
| ▸ | CECR2 | Q9BXF3 | 3/20 | 0.62 |
| ▸ | TAF1 | P21675 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31589675 | 0.86 | BRD4 (0.74) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL17748876 | 0.86 | BRD4 (0.74) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL24866050 | 0.84 | BRD4 (0.76) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL31590527 | 0.83 | BRD4 (0.74) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL17748894 | 0.82 | BRD4 (1.00) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL17749685 | 0.81 | BRD4 (1.00) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL17749684 | 0.81 | BRD4 (1.00) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL31589682 | 0.81 | BRD4 (0.70) | BRD4BRD9CECR2 | |
| SCHEMBL17748888 | 0.81 | BRD4 (1.00) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL28328845 | 0.80 | BRD4 (0.74) | BRD4BRD9CECR2TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | BRD4 560/4885BRD9 280/4885CECR2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.